Published in Circulation on May 14, 2002
Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention. Proc Natl Acad Sci U S A (2005) 2.56
Interference with PPAR gamma function in smooth muscle causes vascular dysfunction and hypertension. Cell Metab (2008) 2.17
Cullin-3 regulates vascular smooth muscle function and arterial blood pressure via PPARγ and RhoA/Rho-kinase. Cell Metab (2012) 1.99
Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J Clin Invest (2003) 1.95
Hypotension, lipodystrophy, and insulin resistance in generalized PPARgamma-deficient mice rescued from embryonic lethality. J Clin Invest (2007) 1.85
Protecting against vascular disease in brain. Am J Physiol Heart Circ Physiol (2011) 1.66
Interference with PPARgamma signaling causes cerebral vascular dysfunction, hypertrophy, and remodeling. Hypertension (2008) 1.55
Endothelium-specific interference with peroxisome proliferator activated receptor gamma causes cerebral vascular dysfunction in response to a high-fat diet. Circ Res (2008) 1.48
Aldosterone-Induced Vascular Remodeling and Endothelial Dysfunction Require Functional Angiotensin Type 1a Receptors. Hypertension (2016) 1.40
Nitro-oleic acid inhibits angiotensin II-induced hypertension. Circ Res (2010) 1.34
PPARs and the cardiovascular system. Antioxid Redox Signal (2009) 1.28
Vascular smooth muscle cell-selective peroxisome proliferator-activated receptor-gamma deletion leads to hypotension. Circulation (2009) 1.25
Disruption of endothelial peroxisome proliferator-activated receptor-gamma reduces vascular nitric oxide production. Am J Physiol Heart Circ Physiol (2009) 1.22
Type II diabetes mellitus and cardiovascular risk factors: Current therapeutic approaches. Exp Clin Cardiol (2007) 1.15
Secreted protein acidic and rich in cysteine deficiency ameliorates renal inflammation and fibrosis in angiotensin hypertension. Am J Pathol (2007) 1.12
Emerging role of mast cells and macrophages in cardiovascular and metabolic diseases. Endocr Rev (2012) 1.11
Rosiglitazone decreases blood pressure and renal injury in a female mouse model of systemic lupus erythematosus. Am J Physiol Regul Integr Comp Physiol (2009) 1.10
Aldosterone does not mediate angiotensin II-induced atherosclerosis and abdominal aortic aneurysms. Br J Pharmacol (2005) 1.10
Peroxisome proliferator-activated receptor-gamma agonists and diabetes: current evidence and future perspectives. Vasc Health Risk Manag (2008) 1.10
PPARs and lipid ligands in inflammation and metabolism. Chem Rev (2011) 1.06
Endothelial and vascular muscle PPARgamma in arterial pressure regulation: lessons from genetic interference and deficiency. Hypertension (2009) 1.06
Bioinformatic analysis of gene sets regulated by ligand-activated and dominant-negative peroxisome proliferator-activated receptor gamma in mouse aorta. Arterioscler Thromb Vasc Biol (2009) 1.05
Exploring metabolic dysfunction in chronic kidney disease. Nutr Metab (Lond) (2012) 1.04
PPARgamma and its ligands: therapeutic implications in cardiovascular disease. Clin Sci (Lond) (2009) 1.03
Distinct functions of vascular endothelial and smooth muscle PPARgamma in regulation of blood pressure and vascular tone. Toxicol Pathol (2008) 1.02
PPAR-gamma in the Cardiovascular System. PPAR Res (2008) 1.01
Does peroxisome proliferator-activated receptor-gamma (PPAR gamma) protect from hypertension directly through effects in the vasculature? J Biol Chem (2010) 1.00
Relaxin causes selective outward remodeling of brain parenchymal arterioles via activation of peroxisome proliferator-activated receptor-γ. FASEB J (2011) 0.98
PPAR{gamma} activation prevents hypertensive remodeling of cerebral arteries and improves vascular function in female rats. Stroke (2010) 0.97
Agonists at PPAR-gamma suppress angiotensin II-induced production of plasminogen activator inhibitor-1 and extracellular matrix in rat cardiac fibroblasts. Br J Pharmacol (2008) 0.95
A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies. Cancer (2012) 0.95
Dual opposing roles of adaptive immunity in hypertension. Eur Heart J (2014) 0.95
The Nuclear Receptor PPARgamma as a Therapeutic Target for Cerebrovascular and Brain Dysfunction in Alzheimer's Disease. Front Aging Neurosci (2010) 0.93
Captopril reduces cardiac inflammatory markers in spontaneously hypertensive rats by inactivation of NF-kB. J Inflamm (Lond) (2010) 0.93
Peroxisome proliferator-activated receptors for hypertension. World J Cardiol (2014) 0.92
Disruption of endothelial peroxisome proliferator-activated receptor γ accelerates diet-induced atherogenesis in LDL receptor-null mice. Arterioscler Thromb Vasc Biol (2011) 0.92
PPARδ activation protects endothelial function in diabetic mice. Diabetes (2012) 0.92
Impaired endothelial function and microvascular asymmetrical dimethylarginine in angiotensin II-infused rats: effects of tempol. Hypertension (2010) 0.91
Transcriptional Control of Vascular Smooth Muscle Cell Proliferation by Peroxisome Proliferator-Activated Receptor-gamma: Therapeutic Implications for Cardiovascular Diseases. PPAR Res (2008) 0.88
Aliskiren prevents and ameliorates metabolic syndrome in fructose-fed rats. Arch Med Sci (2011) 0.88
GW3965, a synthetic liver X receptor (LXR) agonist, reduces angiotensin II-mediated pressor responses in Sprague-Dawley rats. Br J Pharmacol (2007) 0.87
The role of peroxisome proliferator-activated receptors in pulmonary vascular disease. PPAR Res (2007) 0.87
PPARgamma in Kidney Physiology and Pathophysiology. PPAR Res (2009) 0.86
Pioglitazone attenuates vascular fibrosis in spontaneously hypertensive rats. PPAR Res (2012) 0.85
Elevated myocardial Na+/H+ exchanger isoform 1 activity elicits gene expression that leads to cardiac hypertrophy. Physiol Genomics (2010) 0.84
Combination of a peroxisome proliferator-activated receptor-gamma agonist and an angiotensin II receptor blocker attenuates myocardial fibrosis and dysfunction in type 2 diabetic rats. J Diabetes Investig (2013) 0.84
Genetic variations in peroxisome proliferator-activated receptor gamma expression affect blood pressure. Proc Natl Acad Sci U S A (2009) 0.84
Heat shock treatment protects against angiotensin II-induced hypertension and inflammation in aorta. Cell Stress Chaperones (2004) 0.83
Synergistic vascular protective effects of combined low doses of PPARalpha and PPARgamma activators in angiotensin II-induced hypertension in rats. Br J Pharmacol (2007) 0.83
Interference with PPARγ in endothelium accelerates angiotensin II-induced endothelial dysfunction. Physiol Genomics (2015) 0.83
PPARγ activator, rosiglitazone: Is it beneficial or harmful to the cardiovascular system? World J Cardiol (2011) 0.82
Context-dependent effects of SOCS3 in angiotensin II-induced vascular dysfunction and hypertension in mice: mechanisms and role of bone marrow-derived cells. Am J Physiol Heart Circ Physiol (2016) 0.81
PPARγ agonist beyond glucose lowering effect. Korean J Intern Med (2011) 0.81
The impact of severity of hypertension on association of PGC-1alpha gene with blood pressure and risk of hypertension. BMC Cardiovasc Disord (2007) 0.80
Regulation of ENaC-Mediated Sodium Reabsorption by Peroxisome Proliferator-Activated Receptors. PPAR Res (2010) 0.80
Therapeutic Implications of PPARgamma in Cardiovascular Diseases. PPAR Res (2010) 0.79
A clinical link between peroxisome proliferator-activated receptor γ and the renin-angiotensin system. Arterioscler Thromb Vasc Biol (2013) 0.78
Differential effects of short-term treatment with two AT1 receptor blockers on diameter of pial arterioles in SHR. PLoS One (2012) 0.78
Role of vascular smooth muscle PPARγ in regulating AT1 receptor signaling and angiotensin II-dependent hypertension. PLoS One (2014) 0.78
Gene expression microarray analysis of the sciatic nerve of mice with diabetic neuropathy. Int J Mol Med (2014) 0.76
Ghrelin protects against renal damages induced by angiotensin-II via an antioxidative stress mechanism in mice. PLoS One (2014) 0.76
Are thiazolidinediones good or bad for the heart? Curr Diab Rep (2006) 0.76
Pioglitazone treatment increases COX-2-derived prostacyclin production and reduces oxidative stress in hypertensive rats: role in vascular function. Br J Pharmacol (2012) 0.76
Tannic acid down-regulates the angiotensin type 1 receptor through a MAPK-dependent mechanism. Mol Endocrinol (2012) 0.76
Surviving the remodel: the impact of hypertension during pregnancy. Hypertension (2008) 0.75
Changes in Angiotensin Receptor Distribution and in Aortic Morphology Are Associated with Blood Pressure Control in Aged Metabolic Syndrome Rats. Int J Hypertens (2016) 0.75
Effects of a PPAR-gamma receptor agonist and an angiotensin receptor antagonist on aortic contractile responses to alpha receptor agonists in diabetic and/or hypertensive rats. Cardiovasc J Afr (2016) 0.75
Can the electrophysiological action of rosiglitazone explain its cardiac side effects? Curr Med Chem (2011) 0.75
The effect of pioglitazone on aldosterone and cortisol production in HAC15 human adrenocortical carcinoma cells. Mol Cell Endocrinol (2014) 0.75
Protective Actions of PPAR-gamma Activation in Renal Endothelium. PPAR Res (2009) 0.75
The Soluble Epoxide Hydrolase Inhibitor AR9281 Decreases Blood Pressure, Ameliorates Renal Injury and Improves Vascular Function in Hypertension. Pharmaceuticals (Basel) (2009) 0.75
The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol (2010) 5.54
Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med (2003) 4.08
Flavonoids, flavonoid-rich foods, and cardiovascular risk: a meta-analysis of randomized controlled trials. Am J Clin Nutr (2008) 3.84
Endothelial dysfunction. J Am Soc Nephrol (2004) 3.18
Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich) (2013) 2.94
Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens (2014) 2.82
Effectiveness of renal denervation therapy for resistant hypertension: a systematic review and meta-analysis. J Am Coll Cardiol (2013) 2.29
Expression of a functionally active gp91phox-containing neutrophil-type NAD(P)H oxidase in smooth muscle cells from human resistance arteries: regulation by angiotensin II. Circ Res (2002) 2.27
Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol (2011) 2.24
The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part 1- blood pressure measurement, diagnosis and assessment of risk. Can J Cardiol (2005) 2.13
Angiotensin-(1-7) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways. Hypertension (2006) 2.12
T regulatory lymphocytes prevent angiotensin II-induced hypertension and vascular injury. Hypertension (2011) 2.03
The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part II - therapy. Can J Cardiol (2005) 2.03
Inflammation in hypertension. Curr Opin Nephrol Hypertens (2006) 2.01
The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. Can J Cardiol (2007) 2.01
Recommendations for Improving and Standardizing Vascular Research on Arterial Stiffness: A Scientific Statement From the American Heart Association. Hypertension (2015) 2.01
Role of the renin-angiotensin system in vascular inflammation. Trends Pharmacol Sci (2008) 1.97
Endothelial dysfunction as a target for prevention of cardiovascular disease. Diabetes Care (2009) 1.91
The 2012 Canadian hypertension education program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. Can J Cardiol (2012) 1.86
The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol (2013) 1.85
Deficiency of ABCA1 impairs apolipoprotein E metabolism in brain. J Biol Chem (2004) 1.82
Impaired tissue perfusion: a pathology common to hypertension, obesity, and diabetes mellitus. Circulation (2008) 1.82
Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension (2002) 1.81
Lack of pharmacokinetic bioequivalence between generic and branded amoxicillin formulations. A post-marketing clinical study on healthy volunteers. Br J Clin Pharmacol (2009) 1.81
Angiotensin type 2 receptor in resistance arteries of type 2 diabetic hypertensive patients. Hypertension (2006) 1.80
Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions. Clin Sci (Lond) (2007) 1.79
Effects of chocolate, cocoa, and flavan-3-ols on cardiovascular health: a systematic review and meta-analysis of randomized trials. Am J Clin Nutr (2012) 1.78
Involvement of oxidative stress in the profibrotic action of aldosterone. Interaction wtih the renin-angiotension system. Am J Hypertens (2004) 1.67
The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part II - Therapy. Can J Cardiol (2006) 1.67
Endothelium-restricted overexpression of human endothelin-1 causes vascular remodeling and endothelial dysfunction. Circulation (2004) 1.65
Differential regulation of thioredoxin and NAD(P)H oxidase by angiotensin II in male and female mice. J Hypertens (2007) 1.65
The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1--blood pressure measurement, diagnosis and assessment of risk. Can J Cardiol (2009) 1.64
Impaired endothelium-dependent vasodilatation in subclinical hypothyroidism: beneficial effect of levothyroxine therapy. J Clin Endocrinol Metab (2003) 1.61
Angiotensin-(1-7) counterregulates angiotensin II signaling in human endothelial cells. Hypertension (2007) 1.58
Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment. Clin Chem (2008) 1.56
Endothelial nitric oxide synthase uncoupling and perivascular adipose oxidative stress and inflammation contribute to vascular dysfunction in a rodent model of metabolic syndrome. Hypertension (2009) 1.54
Plasma levels of matrix metalloproteinases and their inhibitors in hypertension: a systematic review and meta-analysis. J Hypertens (2012) 1.52
Inhibition of rupture of established atherosclerotic plaques by treatment with apolipoprotein A-I. Cardiovasc Res (2011) 1.51
Inactivation of endothelial proprotein convertase 5/6 decreases collagen deposition in the cardiovascular system: role of fibroblast autophagy. J Mol Med (Berl) (2011) 1.51
Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. J Clin Invest (2005) 1.49
The 2001 Canadian recommendations for the management of hypertension: Part two--Therapy. Can J Cardiol (2002) 1.49
Effect of sulfaphenazole on tissue plasminogen activator release in normotensive subjects and hypertensive patients. Circulation (2009) 1.49
Aldosterone activates vascular p38MAP kinase and NADPH oxidase via c-Src. Hypertension (2005) 1.47
The World Hypertension League and International Society of Hypertension call on governments, nongovernmental organizations, and the food industry to work to reduce dietary sodium. J Clin Hypertens (Greenwich) (2014) 1.44
The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. Can J Cardiol (2010) 1.44
Calcium antagonist treatment by lercanidipine prevents hyperpolarization in essential hypertension. Hypertension (2003) 1.43
Dual angiotensin-converting enzyme/neutral endopeptidase inhibition on cardiac and renal fibrosis and inflammation in DOCA-salt hypertensive rats. J Hypertens (2005) 1.43
Deficiency of T-regulatory cells exaggerates angiotensin II-induced microvascular injury by enhancing immune responses. J Hypertens (2016) 1.43
The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2--therapy. Can J Cardiol (2009) 1.42
Comparison of angiotensin-converting enzyme (ACE), neutral endopeptidase (NEP) and dual ACE/NEP inhibition on blood pressure and resistance arteries of deoxycorticosterone acetate-salt hypertensive rats. J Hypertens (2002) 1.42
Effects of low dietary magnesium intake on development of hypertension in stroke-prone spontaneously hypertensive rats: role of reactive oxygen species. J Hypertens (2002) 1.42
The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part I--Blood pressure measurement, diagnosis and assessment of risk. Can J Cardiol (2006) 1.42
Inhibition of the Jak/STAT signaling pathway prevents the high glucose-induced increase in tgf-beta and fibronectin synthesis in mesangial cells. Diabetes (2002) 1.42
Angiotensin receptor blocker added to previous antihypertensive agents on arteries of diabetic hypertensive patients. Hypertension (2006) 1.40
A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke. JAMA (2004) 1.40
Optimum blood pressure target after lacunar stroke: con side of the argument. Hypertension (2014) 1.39
Tissue-type plasminogen activator release in healthy subjects and hypertensive patients: relationship with beta-adrenergic receptors and the nitric oxide pathway. Hypertension (2008) 1.39
Novel drugs targeting hypertension: renin inhibitors and beyond. J Cardiovasc Pharmacol (2007) 1.39
The 2011 Canadian Hypertension Education Program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. Can J Cardiol (2011) 1.38
T regulatory lymphocytes prevent aldosterone-induced vascular injury. Hypertension (2011) 1.35
Aldosterone: effects on the kidney and cardiovascular system. Nat Rev Nephrol (2010) 1.35
Angiotensin II and endothelin-1 regulate MAP kinases through different redox-dependent mechanisms in human vascular smooth muscle cells. J Hypertens (2004) 1.34
The T-786C and Glu298Asp polymorphisms of the endothelial nitric oxide gene affect the forearm blood flow responses of Caucasian hypertensive patients. J Am Coll Cardiol (2003) 1.33
Redox-dependent signalling by angiotensin II and vascular remodelling in hypertension. Clin Exp Pharmacol Physiol (2003) 1.30
Low-grade systemic inflammation causes endothelial dysfunction in patients with Hashimoto's thyroiditis. J Clin Endocrinol Metab (2006) 1.29
Endothelium-dependent contractions and endothelial dysfunction in human hypertension. Br J Pharmacol (2009) 1.27
Angiotensin II blockade prevents hyperglycemia-induced activation of JAK and STAT proteins in diabetic rat kidney glomeruli. Am J Physiol Renal Physiol (2003) 1.27
Angiotensin type 2 receptor agonist compound 21 reduces vascular injury and myocardial fibrosis in stroke-prone spontaneously hypertensive rats. Hypertension (2011) 1.26
The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. Can J Cardiol (2008) 1.25
Reduced vascular remodeling, endothelial dysfunction, and oxidative stress in resistance arteries of angiotensin II-infused macrophage colony-stimulating factor-deficient mice: evidence for a role in inflammation in angiotensin-induced vascular injury. Arterioscler Thromb Vasc Biol (2005) 1.24
Role of NAD(P)H oxidase on vascular alterations in angiotensin II-infused mice. J Hypertens (2004) 1.23
Treatment of arterial remodeling in essential hypertension. Curr Hypertens Rep (2013) 1.22
Hyperinsulinemia is associated with increased production rate of intestinal apolipoprotein B-48-containing lipoproteins in humans. Arterioscler Thromb Vasc Biol (2006) 1.22
Vascular mechanisms in the pathogenesis of stroke. Curr Hypertens Rep (2011) 1.21
ETA receptor blockade decreases vascular superoxide generation in DOCA-salt hypertension. Hypertension (2003) 1.20
The 2004 Canadian Hypertension Education Program recommendations for the management of hypertension: Part I--Blood pressure measurement, diagnosis and assessment of risk. Can J Cardiol (2004) 1.20
Vascular inflammation: a role in vascular disease in hypertension? Curr Opin Nephrol Hypertens (2003) 1.19
The eye and the heart. Eur Heart J (2013) 1.18
Aldosterone-induced activation of signaling pathways requires activity of angiotensin type 1a receptors. Circ Res (2009) 1.17
Isolated aerobic exercise and weight loss: a systematic review and meta-analysis of randomized controlled trials. Am J Med (2011) 1.16
PPAR alpha activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats. J Mol Cell Cardiol (2004) 1.16
Nitric oxide, oxidative excess, and vascular complications of diabetes mellitus. Curr Hypertens Rep (2004) 1.15
Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications. Vascul Pharmacol (2006) 1.15